What Lies Beneath: The Developer Building a Data Center on a Former Army Dump Laced With Munitions and Carcinogens
Digital Realty paid $120 million for Atlanta-area parcels including a former Army dump with buried carcinogens and military ordnance.
Digital Realty paid $120 million for Atlanta-area parcels including a former Army dump with buried carcinogens and military ordnance.
@HiddenGemsInves $CHCI ° Asset light, high ROIC asset manager ° Track record of revenue, FCF growth, clear strategy ° ~30% owned by Dwight Shar, founder/former CEO of $NVR ° move into data center development is a potential grand slam - a cheap call option
*GOPRO SHARES EXTEND THREE-DAY RALLY TO MORE THAN 180% $GPRO up another 40% today despite the merger announcement yesterday https://t.co/ChwU3GIvrX
@simcity31 $ORR has been a great investment and I'm happy with it. I just don't think any investment should be sized as large as I sized it. https://t.co/HnwLbpAPID
@ridireresearch Why $PURR instead of $THYP?
@GrumpierBTDay @vanillager Off topic, but have you looked at $AERG?
$KLAR seems too easy… obviously recession=write-offs, but the value proposition to consumers would strengthen? What am I missing?
Everything is going right for Apes. Box office last month was an all time record. And the Apes can't get $AMC above $3 or should I say 30 cents before the reverse split. Only conclusion I have: Apes weak, Ken Griffin strong. Be like Ken Griffin.
$APTV This RemainCo looks cheap, but ugly looking chart... https://t.co/GTJKSyt0ew
Optical-component vendor call covers 800G and 1.6T demand, AI cluster optical density, market share, pricing and 2027 growth for Coherent,…
SiriusXM trades at 6.5 times free cash flow, a 15% yield, with high short interest and catalysts that could drive a short squeeze.
Steve Eisman examines AI data-center debt, CoreWeave's tech correction and agentic AI's effect on banks as earnings season begins.
RELX’s 13-petabyte fraud and identity data moat supports its high-margin Risk segment as its valuation falls to roughly half its peak P/E.
Gloo's $3.25 follow-on, going-concern warning and $28.0 million first-half cash burn frame the short case against its acquisition-driven…
Tower Properties, $TPRP, went dark after a 2006 squeeze-out cut holders below 300, leaving a Kemper-controlled apartment and office…
Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.
Dorchester Minerals' 9.5% normalized yield and debt-free royalty model are offset by limited upside at $29.71, as extraordinary…
Tuya’s $976 million cash pile equals 94% of its $1.04 billion market cap as its smart-home platform returned to 16% revenue growth in Q2…
Fannie Mae and Freddie Mac could leave conservatorship through a 2026 restructuring and IPO, monetizing the government’s equity stake while…
FINV · long FinVolution, a China and ASEAN unsecured consumer lender, trades at 4x earnings and 0.5x book value.
DexCom’s 15-day G7 sensor lifted Q2 2026 gross margin 400 basis points to 64.1%, lowering CGM costs ahead of broader Type 2 diabetes…
CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.
PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…
Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…
CoreWeave’s 2032 notes yield over 15%, signaling a 54% default probability as borrowing costs exceed rental yields on AI infrastructure…
AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…
Dream Finders Homes’ controlling owner borrowed against DFH stock before the homebuilder agreed to finance an acquisition with costly…
Park Aerospace’s 11% Q2’27 sell-off overlooks sole-source PAC-3 rocket-motor materials and A320neo engine composites, with missile capacity…
UniQure's Huntington's gene therapy faces an FDA accelerated-approval decision around November 1 after three-year data met both agency…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.